Zdrowie i gospodarka · 21/01/1999

FDA Releases Draft Guidance on Reporting Impurities in Drug Substances

The Food and Drug Administration (FDA) has made available a draft guidance document that advises pharmaceutical companies on how to report impurities in drug substances when submitting new drug applications (NDAs) or supporting documents, in line with the International Conference on Harmonisation (ICH) Q3A guidance.